Schrodinger, INC. (SDGR) — SEC Filings

Q: What are the key financial highlights for Schrodinger, INC.?

Key financial highlights for Schrodinger, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Schrodinger, INC.?

Key executives at Schrodinger, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Schrodinger, INC. stock?

Risk factors for Schrodinger, INC. (SDGR) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Schrodinger, INC.?

Forward-looking statements and predictions from Schrodinger, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Schrodinger, INC.. Recent 8-K filing on Nov 5, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Schrodinger, INC. on SEC EDGAR

Overview

Schrodinger, INC. (SDGR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 5, 2025: Schrodinger, Inc. filed an 8-K on November 5, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located at 1540 Broadway, 24th Floor, New Yo

Sentiment Summary

Across 23 filings, the sentiment breakdown is: 22 neutral, 1 mixed. The dominant filing sentiment for Schrodinger, INC. is neutral.

Filing Type Overview

Schrodinger, INC. (SDGR) has filed 10 8-K, 5 10-Q, 2 DEF 14A, 2 10-K, 1 SC 13G, 1 DEFA14A, 2 SC 13G/A with the SEC between Jan 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (23)

Schrodinger, Inc. Files 8-K on Financials — 8-K · Nov 5, 2025 Risk: low
Schrodinger, Inc. filed an 8-K on November 5, 2025, reporting on its results of operations and financial condition. The filing also includes financial statement
Schrodinger Announces Director Changes and Compensation Updates — 8-K · Sep 8, 2025 Risk: medium
Schrodinger, Inc. announced on September 5, 2025, changes related to its board of directors and executive compensation. The filing details the departure of cert
Schrodinger's Q2: Software Shines, Drug Discovery Dips — 10-Q · Aug 6, 2025 Risk: medium
Schrodinger, Inc. reported a mixed financial performance for Q2 2025, with total revenue for the three months ended June 30, 2025, reaching $55.2 million, a dec
Schrodinger, Inc. Files 8-K on Security Holder Votes — 8-K · Jun 18, 2025 Risk: low
Schrodinger, Inc. filed an 8-K on June 18, 2025, to report on matters submitted to a vote of its security holders. The filing details the company's corporate st
Schrodinger, Inc. Files 8-K: Director/Officer Changes & Financials — 8-K · May 20, 2025 Risk: medium
Schrödinger, Inc. filed an 8-K on May 20, 2025, reporting events as of May 16, 2025. The filing indicates changes related to the departure of directors or certa
Schrodinger, Inc. Files 8-K — 8-K · May 19, 2025 Risk: low
Schrödinger, Inc. filed an 8-K on May 19, 2025, to report other events. The filing does not contain specific details about the nature of these events, dollar am
Schrodinger Files Q1 2025 10-Q — 10-Q · May 7, 2025 Risk: medium
Schrodinger, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter of
Schrodinger Files DEF 14A, Details Executive Equity Awards — DEF 14A · Apr 24, 2025 Risk: medium
Schrodinger, Inc. filed its DEF 14A on April 24, 2025, detailing executive compensation and other corporate matters for the fiscal year ending December 31, 2024
Schrodinger, Inc. Files 8-K for Other Events & Exhibits — 8-K · Apr 11, 2025 Risk: low
Schrodinger, Inc. filed an 8-K on April 11, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not detail specific transact
Schrodinger CEO Departs, New CEO Appointed — 8-K · Mar 10, 2025 Risk: medium
Schrodinger, Inc. announced on March 7, 2025, the departure of Dr. Ramy Farid from his role as Chief Executive Officer and President, effective March 10, 2025.
10-K Filing — 10-K · Feb 26, 2025
SC 13G Filing — SC 13G · Nov 13, 2024
Schrodinger Files Q3 2024 10-Q — 10-Q · Nov 12, 2024 Risk: medium
Schrodinger, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results for the third quarter and the first nine month
Schrodinger, Inc. Enters Material Definitive Agreement — 8-K · Sep 12, 2024 Risk: medium
Schrodinger, Inc. announced on September 11, 2024, that it has entered into a material definitive agreement. The company, incorporated in Delaware, filed an 8-K
Schrodinger Files 10-Q for Q2 2024 — 10-Q · Jul 31, 2024 Risk: medium
Schrodinger, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results for the second quarter and the first half of the ye
Schrodinger Announces Director Changes and Executive Compensation — 8-K · Jun 18, 2024 Risk: low
Schrodinger, Inc. announced on June 18, 2024, the departure of Director Dr. Christopher J. Alport and the election of Dr. David E. R. Sutherland as a new Class
Schrödinger Files 2024 Annual Meeting Proxy Supplement — DEFA14A · May 30, 2024 Risk: low
Schrödinger, Inc. is filing a supplemental proxy statement for its 2024 Annual Meeting of Stockholders, scheduled for June 18, 2024. This filing provides additi
Schrodinger, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 1, 2024 Risk: medium
Schrodinger, Inc. (SDGR) filed a Quarterly Report (10-Q) with the SEC on May 1, 2024. Schrodinger, Inc. reported financial results for the quarter ended March 3
Schrodinger, Inc. DEF 14A Filing — DEF 14A · Apr 25, 2024 Risk: low
Schrodinger, Inc. (SDGR) filed a Proxy Statement (DEF 14A) with the SEC on April 25, 2024. Filing type is DEF 14A, filed on 2024-04-25. Company Name: Schrodinge
Schrodinger Enters Material Definitive Agreement — 8-K · Feb 29, 2024 Risk: medium
Schrodinger, Inc. filed an 8-K on February 28, 2024, to report the entry into a material definitive agreement. The filing indicates the company's business addre
Schrodinger, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 28, 2024 Risk: medium
Schrodinger, Inc. (SDGR) filed a Annual Report (10-K) with the SEC on February 28, 2024. Schrodinger, Inc. filed its 2023 Form 10-K on February 28, 2024. The fi
SC 13G/A Filing — SC 13G/A · Feb 13, 2024
BlackRock Maintains Significant Passive Stake in Schrodinger, Inc. — SC 13G/A · Jan 23, 2024
BlackRock Inc. filed an amended SC 13G/A on January 23, 2024, disclosing its ownership in Schrodinger, Inc. as of December 31, 2023. This filing, Amendment No.

Risk Profile

Risk Assessment: Of SDGR's 19 recent filings, 0 were flagged as high-risk, 12 as medium-risk, and 7 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Schrodinger, INC.'s most recent 10-Q filing (Aug 6, 2025):

Revenue: $55.2M
Net Income: -$45.1M
Cash Position: $451.0M

Key Executives

Dr. Ramy Farid
Dr. Karen Akins
Dr. Christopher J. Alport
Dr. David E. R. Sutherland

Industry Context

Schrodinger, Inc. operates in the pharmaceutical preparations sector, leveraging computational chemistry for drug discovery and development. The industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Schrodinger aim to accelerate drug discovery through advanced software platforms, facing competition from both established pharmaceutical giants and other specialized biotech firms.

Top Tags

financials (4) · 10-Q (4) · executive-compensation (3) · software (3) · Schrodinger (3) · filing (2) · governance (2) · board-changes (2) · Drug Discovery (2) · Pharmaceuticals (2)

Key Numbers

Total Revenue Q2 2025: $55.2M — Decreased from $61.5M in Q2 2024, indicating an overall revenue decline.
Software Revenue Q2 2025: $35.8M — Increased 11.5% from $32.1M in Q2 2024, showing strength in the core software business.
Drug Discovery Revenue Q2 2025: $19.4M — Decreased 34% from $29.4M in Q2 2024, highlighting significant volatility in this segment.
Net Loss Q2 2025: -$45.1M — Improved from -$52.3M in Q2 2024, indicating a narrowing of losses.
Accumulated Deficit: $1.02B — Increased from $934.5M at year-end 2024, reflecting continued operational losses.
Cash and Cash Equivalents: $451.0M — As of June 30, 2025, providing liquidity for ongoing operations.
Reporting Period End Date: 2025-03-31 — Indicates the end of the financial quarter being reported.
Reporting Period Start Date: 2025-01-01 — Indicates the start of the financial quarter being reported.
Fiscal Years Covered: 2020-2024 — Information on equity awards for these years is detailed.
SEC File Number: 001-39206 — Identifies the company's filing with the SEC.
EIN: 95-4284541 — Employer Identification Number for tax purposes.
Reporting Period: Q3 2024 — Third quarter financial results
Business Segment: Software Products and Services — Revenue source detailed in the filing
IRS Employer Identification No.: 95-4284541 — Schrodinger's tax identification number.
Filing Date: 2024-07-31 — The date the 10-Q was officially submitted to the SEC.

Related Companies

SCHR

Frequently Asked Questions

What are the latest SEC filings for Schrodinger, INC. (SDGR)?

Schrodinger, INC. has 23 recent SEC filings from Jan 2024 to Nov 2025, including 10 8-K, 5 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of SDGR filings?

Across 23 filings, the sentiment breakdown is: 22 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Schrodinger, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Schrodinger, INC. (SDGR) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Schrodinger, INC.?

Key financial highlights from Schrodinger, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for SDGR?

The investment thesis for SDGR includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Schrodinger, INC.?

Key executives identified across Schrodinger, INC.'s filings include Dr. Ramy Farid, Dr. Karen Akins, Dr. Christopher J. Alport, Dr. David E. R. Sutherland.

What are the main risk factors for Schrodinger, INC. stock?

Of SDGR's 19 assessed filings, 0 were flagged high-risk, 12 medium-risk, and 7 low-risk.

What are recent predictions and forward guidance from Schrodinger, INC.?

Forward guidance and predictions for Schrodinger, INC. are extracted from SEC filings as they are enriched.